ATE509948T1 - Fusionpeptid zum inhibieren der wechselwirkung des neuronalen nmda-rezeptors (nmdar) mit nmdar- wechselwirkenden proteinen - Google Patents
Fusionpeptid zum inhibieren der wechselwirkung des neuronalen nmda-rezeptors (nmdar) mit nmdar- wechselwirkenden proteinenInfo
- Publication number
- ATE509948T1 ATE509948T1 AT07786341T AT07786341T ATE509948T1 AT E509948 T1 ATE509948 T1 AT E509948T1 AT 07786341 T AT07786341 T AT 07786341T AT 07786341 T AT07786341 T AT 07786341T AT E509948 T1 ATE509948 T1 AT E509948T1
- Authority
- AT
- Austria
- Prior art keywords
- nmdar
- fusion peptide
- component
- interaction
- interacting proteins
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 5
- 230000004927 fusion Effects 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06015911A EP1884521A1 (de) | 2006-07-31 | 2006-07-31 | Fusionspeptide zur Hemmung der Wechselwirkung zwischen den neuronalen NDMA Rezeptor und damit NMDAR interagierende Proteine |
PCT/EP2007/006619 WO2008014917A1 (en) | 2006-07-31 | 2007-07-25 | Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE509948T1 true ATE509948T1 (de) | 2011-06-15 |
Family
ID=37084687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07786341T ATE509948T1 (de) | 2006-07-31 | 2007-07-25 | Fusionpeptid zum inhibieren der wechselwirkung des neuronalen nmda-rezeptors (nmdar) mit nmdar- wechselwirkenden proteinen |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090281036A1 (de) |
EP (2) | EP1884521A1 (de) |
JP (1) | JP2009545543A (de) |
KR (1) | KR20090033868A (de) |
CN (1) | CN101490081A (de) |
AT (1) | ATE509948T1 (de) |
AU (1) | AU2007280717A1 (de) |
BR (1) | BRPI0714783A2 (de) |
CA (1) | CA2653438A1 (de) |
HR (1) | HRP20080648A2 (de) |
IL (1) | IL195536A0 (de) |
MX (1) | MX2009001095A (de) |
NO (1) | NO20090875L (de) |
RU (1) | RU2009106710A (de) |
WO (1) | WO2008014917A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5746468B2 (ja) | 2006-07-11 | 2015-07-08 | ノノ インコーポレイテッド | 発熱を伴う脳卒中を処置する方法および組成物 |
US8933013B2 (en) | 2007-12-05 | 2015-01-13 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
GB0804496D0 (en) | 2008-03-11 | 2008-04-16 | Theryte Ltd | Treating cancer |
ES2446306T3 (es) * | 2008-05-16 | 2014-03-07 | Nono Inc. | Uso de un inhibidor de psd-95 tratamiento para la epilepsia |
WO2010028089A2 (en) | 2008-09-03 | 2010-03-11 | Arbor Vita Corporation | Agents and methods for treatment of pain |
PL2440230T3 (pl) * | 2009-06-10 | 2021-06-14 | Nono Inc. | Schematy leczenia do leczenia choroby neurologicznej |
WO2012021854A2 (en) * | 2010-08-12 | 2012-02-16 | Nono, Inc. | Treatment of penetrative injury to the brain |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2012158624A2 (en) | 2011-05-13 | 2012-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of mitochondrial fission and methods of use thereof |
PL2723363T3 (pl) | 2011-06-24 | 2018-12-31 | Nono Inc. | Leczenie skojarzone niedokrwienia |
WO2013054110A2 (en) * | 2011-10-10 | 2013-04-18 | University Of Lancaster | Compositions for binding to amyloid proteins |
AU2012354072B2 (en) * | 2011-12-13 | 2017-04-27 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CA2892965C (en) * | 2012-11-28 | 2021-06-01 | Nono Inc. | Lyophilized formulation of tat-nr2b9c |
US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
US20140296164A1 (en) * | 2013-03-29 | 2014-10-02 | Calista Therapeutics, Inc. | Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand |
WO2014206563A2 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
ES2724932T3 (es) | 2013-10-30 | 2019-09-17 | Univ Western Australia | Péptidos neuroprotectores |
CN103804500B (zh) * | 2014-01-22 | 2015-12-30 | 广州军区广州总医院 | 用于治疗慢性疼痛的多肽 |
JP6625071B2 (ja) * | 2014-03-07 | 2019-12-25 | ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性crmp2ペプチド |
CN103936838B (zh) * | 2014-04-10 | 2015-10-28 | 武汉启瑞科技发展有限公司 | 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用 |
CN106661126B (zh) | 2014-05-28 | 2021-12-10 | 诺诺公司 | TAT-NR2B9c的氯盐 |
US10206878B2 (en) | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
EP3190129B1 (de) * | 2014-09-02 | 2020-01-08 | Tokyo University of Science Foundation | Zentral wirkendes peptidderivat und pharmazeutische zusammensetzung |
CN104650242A (zh) * | 2015-01-13 | 2015-05-27 | 河南科技大学 | 一种融合多肽及其制备方法和应用 |
JP6958913B2 (ja) * | 2015-11-06 | 2021-11-02 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | 心停止の処置のためのペプチドおよび方法 |
US11229675B2 (en) * | 2016-04-27 | 2022-01-25 | Biocells (Beijing) Biotech Co., Ltd. | Therapeutic peptides for excitatory neurotoxicity-related injuries |
WO2018085436A1 (en) * | 2016-11-01 | 2018-05-11 | Memorial Sloan Kettering Cancer Center | Agents and methods for treating creb binding protein-dependent cancers |
CN110049994B (zh) * | 2016-12-08 | 2023-05-02 | 拜西欧斯(北京)生物技术有限公司 | 一种缀合物及其应用 |
EP3784261A4 (de) * | 2017-04-02 | 2021-11-03 | InterK Peptide Therapeutics Limited | Zusammensetzungen und verfahren zur prophylaxe oder behandlung von schmerzen |
JP7002788B2 (ja) * | 2017-07-05 | 2022-03-03 | 拜西欧斯(北京)生物技術有限公司 | ポリペプチドの薬学的に許容される塩およびその使用 |
WO2019006692A1 (zh) * | 2017-07-05 | 2019-01-10 | 拜西欧斯(北京)生物技术有限公司 | 用于治疗、改善或预防神经系统相关病症的化合物及其用途 |
EP4006057A4 (de) | 2019-07-11 | 2023-08-09 | Xiamen University | Komplex zur intrazellulären abgabe von molekülen |
WO2021135647A1 (zh) | 2019-12-31 | 2021-07-08 | 厦门大学 | 用于胞内递送分子的多聚化递送系统 |
US20230055441A1 (en) * | 2020-01-09 | 2023-02-23 | Nono Inc. | Plasmin-resistant peptides for treating stroke and related conditions |
CN114539358B (zh) * | 2020-11-19 | 2023-09-15 | 中国科学院大连化学物理研究所 | 一种多肽及制备方法与应用 |
CN112853559B (zh) * | 2020-12-31 | 2021-10-08 | 盐城师范学院 | 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法 |
CN113735938A (zh) * | 2021-07-30 | 2021-12-03 | 英纳氏(珠海)药业有限公司 | 一种神经保护多肽化合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023781A1 (en) * | 1996-11-26 | 1998-06-04 | Johns Hopkins University | Ligand detection system and methods of use thereof |
US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
EP1578365A4 (de) * | 2002-11-14 | 2009-09-23 | Arbor Vita Corp | Molekulare interaktionen in neuronen |
-
2006
- 2006-07-31 EP EP06015911A patent/EP1884521A1/de not_active Withdrawn
-
2007
- 2007-07-25 AT AT07786341T patent/ATE509948T1/de not_active IP Right Cessation
- 2007-07-25 KR KR1020097000709A patent/KR20090033868A/ko not_active Application Discontinuation
- 2007-07-25 US US12/375,886 patent/US20090281036A1/en not_active Abandoned
- 2007-07-25 CA CA002653438A patent/CA2653438A1/en not_active Abandoned
- 2007-07-25 CN CNA200780027425XA patent/CN101490081A/zh active Pending
- 2007-07-25 RU RU2009106710/10A patent/RU2009106710A/ru unknown
- 2007-07-25 BR BRPI0714783-0A patent/BRPI0714783A2/pt not_active IP Right Cessation
- 2007-07-25 JP JP2009522146A patent/JP2009545543A/ja active Pending
- 2007-07-25 EP EP07786341A patent/EP2046821B1/de not_active Not-in-force
- 2007-07-25 MX MX2009001095A patent/MX2009001095A/es not_active Application Discontinuation
- 2007-07-25 WO PCT/EP2007/006619 patent/WO2008014917A1/en active Application Filing
- 2007-07-25 AU AU2007280717A patent/AU2007280717A1/en not_active Abandoned
-
2008
- 2008-11-26 IL IL195536A patent/IL195536A0/en unknown
- 2008-12-12 HR HR20080648A patent/HRP20080648A2/xx not_active Application Discontinuation
-
2009
- 2009-02-25 NO NO20090875A patent/NO20090875L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL195536A0 (en) | 2011-08-01 |
CN101490081A (zh) | 2009-07-22 |
CA2653438A1 (en) | 2008-02-07 |
EP1884521A1 (de) | 2008-02-06 |
KR20090033868A (ko) | 2009-04-06 |
JP2009545543A (ja) | 2009-12-24 |
WO2008014917A1 (en) | 2008-02-07 |
EP2046821A1 (de) | 2009-04-15 |
MX2009001095A (es) | 2009-02-10 |
AU2007280717A1 (en) | 2008-02-07 |
HRP20080648A2 (en) | 2009-02-28 |
RU2009106710A (ru) | 2010-09-10 |
BRPI0714783A2 (pt) | 2013-07-30 |
US20090281036A1 (en) | 2009-11-12 |
NO20090875L (no) | 2009-02-25 |
EP2046821B1 (de) | 2011-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE509948T1 (de) | Fusionpeptid zum inhibieren der wechselwirkung des neuronalen nmda-rezeptors (nmdar) mit nmdar- wechselwirkenden proteinen | |
BRPI0809366B8 (pt) | polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica | |
ATE491349T1 (de) | Neue nutrazeutika-zusammensetzungen | |
RS50966B (sr) | Agonisti pyy i njihova upotreba | |
WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
MY161664A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
JOP20190083A1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
ATE531727T1 (de) | Bioaktive peptide und verfahren zu ihrer verwendung | |
BRPI0509903A (pt) | uso de compostos peptìdicos para profilaxia e tratamento da cefaléia crÈnica | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
EA200802128A1 (ru) | Новые нутрицевтические композиции | |
CY1112185T1 (el) | Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη | |
SI1848458T1 (sl) | Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov | |
WO2006042745A3 (de) | Chemisch modifizierte iapp - peptidanaloga | |
DK1492761T3 (da) | Aminosyrer med affinitet til alpha-2-delta-proteinet | |
NO20044564L (no) | Fremgangsmater for behandling av nekrotiserende enterocolit | |
WO2008093058A3 (en) | Peptides and their use | |
WO2005074626A3 (en) | Compositions, methods and uses for a novel family of peptides | |
PL1972637T3 (pl) | Antagoniści selektywni wobec huTNFR1 | |
IL223076A0 (en) | Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics | |
BR112012007563A2 (pt) | peptídeos sintéticos antagonistas de miostatina | |
WO2006110724A3 (en) | Method of treating schizophrenia prodrome | |
BRPI0505090A (pt) | composição de toner | |
BRPI0516922A (pt) | composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |